236 related articles for article (PubMed ID: 27529836)
1. Prospective Analyses of Circulating B Cell Subsets in ABO-Compatible and ABO-Incompatible Kidney Transplant Recipients.
Schlößer HA; Thelen M; Dieplinger G; von Bergwelt-Baildon A; Garcia-Marquez M; Reuter S; Shimabukuro-Vornhagen A; Wennhold K; Haustein N; Buchner D; Heiermann N; Kleinert R; Wahba R; Ditt V; Kurschat C; Cingöz T; Becker J; Stippel DL; von Bergwelt-Baildon M
Am J Transplant; 2017 Feb; 17(2):542-550. PubMed ID: 27529836
[TBL] [Abstract][Full Text] [Related]
2. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone.
Masterson R; Hughes P; Walker RG; Hogan C; Haeusler M; Robertson AR; Millar R; Suh N; Cohney SJ
Am J Transplant; 2014 Dec; 14(12):2807-13. PubMed ID: 25389083
[TBL] [Abstract][Full Text] [Related]
3. ABO-incompatible pediatric kidney transplantation without antibody removal.
Kawamura T; Hamasaki Y; Takahashi Y; Hashimoto J; Kubota M; Muramatu M; Itabashi Y; Hyodo Y; Ohashi Y; Aikawa A; Sakai K; Shishido S
Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
5. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
[TBL] [Abstract][Full Text] [Related]
6. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
8. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
9. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.
Barnett AN; Manook M; Nagendran M; Kenchayikoppad S; Vaughan R; Dorling A; Hadjianastassiou VG; Mamode N
Transpl Int; 2014 Feb; 27(2):187-96. PubMed ID: 24188566
[TBL] [Abstract][Full Text] [Related]
10. [The kidney transplantation from the ABO-incompatible donors].
Goriaĭnov VA; Kaabak MM; Babenko NN; Shishlo LA; Morozova MM; Ragimov AA; Dashkova NG; Salimov ÉL
Khirurgiia (Mosk); 2012; (7):70-4. PubMed ID: 22968508
[TBL] [Abstract][Full Text] [Related]
11. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.
Ishida H; Kondo T; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2015 Mar; 28(3):286-96. PubMed ID: 25363583
[TBL] [Abstract][Full Text] [Related]
12. Outcomes, complications, and economic impact of ABO-incompatible living kidney transplantation: A single-center Japanese cohort study.
Kakuta Y; Okumi M; Unagami K; Iizuka J; Takagi T; Ishida H; Tanabe K
Clin Transplant; 2019 Jun; 33(6):e13591. PubMed ID: 31077450
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
14. Acute Cellular Rejection in ABO-Incompatible Renal Transplant Recipients Receiving Rituximab Is Associated with Delayed-Onset Neutropenia.
Uchida J; Iwai T; Nishide S; Kabei K; Kuwabara N; Yamasaki T; Naganuma T; Kumada N; Takemoto Y; Nakatani T
Ann Transplant; 2017 Jul; 22():455-462. PubMed ID: 28740069
[TBL] [Abstract][Full Text] [Related]
15. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
16. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.
Koch M; Wiech T; Marget M; Peine S; Thude H; Achilles EG; Fischer L; Lehnhardt A; Thaiss F; Nashan B
Clin Transplant; 2015 Nov; 29(11):1021-8. PubMed ID: 26333844
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation.
Del Bello A; Divard G; Belliere J; Congy-Jolivet N; Lanfranco L; Ricard R; Delas A; Colombat M; Esposito L; Hebral AL; Cointault O; Lefaucheur C; Loupy A; Kamar N
Clin Transplant; 2019 Oct; 33(10):e13681. PubMed ID: 31369170
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience.
Tanabe K; Takahashi K; Sonda K; Tokumoto T; Ishikawa N; Kawai T; Fuchinoue S; Oshima T; Yagisawa T; Nakazawa H; Goya N; Koga S; Kawaguchi H; Ito K; Toma H; Agishi T; Ota K
Transplantation; 1998 Jan; 65(2):224-8. PubMed ID: 9458019
[TBL] [Abstract][Full Text] [Related]
19. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
20. Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.
Nishimura H; Yamada Y; Hisano S; Mitsuke A; Tatarano S; Gotanda T; Hayami H; Nakagawa M; Enokida H
BMC Nephrol; 2018 Oct; 19(1):254. PubMed ID: 30290778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
